Dage Bio is a molecular glue targeted protein degradation technology and new drug developer. Starting from a new chemical skeleton discovered by Professor Cang Yong’s laboratory, it has created Lenalidomide, which is commonly used with other molecular glue companies. A unique compound library different from Pomalidomide derivatives, and through the company’s continuous exploration and data accumulation, the number of compound libraries and the diversity of parent nuclei have been expanded, and patent protection has been formed. Recently, Dago Bio completed a $32 million A+ round of financing, and the investor did not disclose it.
This article is reproduced from: https://www.itjuzi.com/investevent/13468236
This site is for inclusion only, and the copyright belongs to the original author.